On Monday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) opened higher 4.49% from the last session, before settling in for the closing price of $30.51. Price fluctuations for CRNX have ranged from $24.10 to $62.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -22.35% at the time writing. With a float of $86.78 million, this company’s outstanding shares have now reached $93.53 million.
Let’s look at the performance matrix of the company that is accounted for 437 employees. In terms of profitability, gross margin is 0.92%, operating margin of -49569.74%, and the pretax margin is -43191.05%.
Crinetics Pharmaceuticals Inc (CRNX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Crinetics Pharmaceuticals Inc is 7.37%, while institutional ownership is 105.00%. The most recent insider transaction that took place on Mar 19 ’25, was worth 86,021. In this transaction Chief Med and Dev Officer of this company sold 2,515 shares at a rate of $34.20, taking the stock ownership to the 72,233 shares. Before that another transaction happened on Mar 19 ’25, when Company’s Chief Operating Officer sold 7,162 for $34.20, making the entire transaction worth $244,964. This insider now owns 87,491 shares in total.
Crinetics Pharmaceuticals Inc (CRNX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -22.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.12% during the next five years compared to -12.11% drop over the previous five years of trading.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Check out the current performance indicators for Crinetics Pharmaceuticals Inc (CRNX). In the past quarter, the stock posted a quick ratio of 22.53. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8295.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.82, a number that is poised to hit -1.10 in the next quarter and is forecasted to reach -4.69 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) saw its 5-day average volume 1.04 million, a positive change from its year-to-date volume of 1.02 million. As of the previous 9 days, the stock’s Stochastic %D was 66.12%. Additionally, its Average True Range was 1.61.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 28.86%, which indicates a significant decrease from 64.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.67% in the past 14 days, which was lower than the 63.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.28, while its 200-day Moving Average is $44.34. Nevertheless, the first resistance level for the watch stands at $32.53 in the near term. At $33.19, the stock is likely to face the second major resistance level. The third major resistance level sits at $34.38. If the price goes on to break the first support level at $30.68, it is likely to go to the next support level at $29.49. Assuming the price breaks the second support level, the third support level stands at $28.83.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
There are currently 93,629K shares outstanding in the company with a market cap of 2.99 billion. Presently, the company’s annual sales total 1,040 K according to its annual income of -298,410 K. Last quarter, the company’s sales amounted to 360 K and its income totaled -96,770 K.
